These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25839886)

  • 1. Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma.
    Ramani NS; Curry JL; Kapil J; Rapini RP; Tetzlaff MT; Prieto VG; Torres-Cabala CA
    Am J Dermatopathol; 2015 Aug; 37(8):e96-9. PubMed ID: 25839886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
    Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
    Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
    Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
    J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
    [No Abstract]   [Full Text] [Related]  

  • 5. Panniculitis in patients treated with BRAF inhibitors: a case series.
    Choy B; Chou S; Anforth R; Fernández-Peñas P
    Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
    Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
    Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous granulomatous panniculitis and sarcoidal granulomatous papular eruption in a patient with metastatic melanoma treated with a BRAF inhibitor.
    Leal L; Agut-Busquet E; Romani J; Sabat M; Yebenes M; Saez A; Luelmo J
    J Dermatol; 2016 Jun; 43(6):715-6. PubMed ID: 26777901
    [No Abstract]   [Full Text] [Related]  

  • 11. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
    Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.
    Sanlorenzo M; Choudhry A; Vujic I; Posch C; Chong K; Johnston K; Meier M; Osella-Abate S; Quaglino P; Daud A; Algazi A; Rappersberger K; Ortiz-Urda S
    J Am Acad Dermatol; 2014 Dec; 71(6):1102-1109.e1. PubMed ID: 25440439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Tolk H; Satzger I; Mohr P; Zimmer L; Weide B; Schäd S; Gutzmer R
    Melanoma Res; 2015 Aug; 25(4):362-6. PubMed ID: 26061438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
    Consoli F; Manganoni AM; Grisanti S; Petrelli F; Venturini M; Rangoni G; Guarneri F; Incardona P; Vermi W; Calzavara Pinton PG; Berruti A
    PLoS One; 2019; 14(4):e0214884. PubMed ID: 30939167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
    Hauschild A; Ascierto PA; Schadendorf D; Grob JJ; Ribas A; Kiecker F; Dutriaux C; Demidov LV; Lebbé C; Rutkowski P; Blank CU; Gutzmer R; Millward M; Kefford R; Haas T; D'Amelio A; Gasal E; Mookerjee B; Chapman PB
    Eur J Cancer; 2020 Jan; 125():114-120. PubMed ID: 31864178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib-associated necrobiotic granulomatous reaction.
    Carlos G; Anforth R; Chou S; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):306-8. PubMed ID: 25399793
    [No Abstract]   [Full Text] [Related]  

  • 18. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
    Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
    J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.